Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Corvus Pharmaceuticals, Inc. (CRVS : NSDQ)
 
 • Company Description   
Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California.

Number of Employees: 31

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.98 Daily Weekly Monthly
20 Day Moving Average: 1,194,589 shares
Shares Outstanding: 68.17 (millions)
Market Capitalization: $271.31 (millions)
Beta: 0.58
52 Week High: $10.00
52 Week Low: $1.75
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 6.13% 1.76%
12 Week 35.37% 18.62%
Year To Date -25.61% -29.74%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
901 Gateway Boulevard Third Floor
-
South San Francisco,CA 94080
USA
ph: 650-900-4520
fax: -
llea@corvuspharma.com http://www.corvuspharma.com
 
 • General Corporate Information   
Officers
Richard A. Miller - President; Chief Executive Officer and Director
Leiv Lea - Chief Financial Officer
Ian T. Clark - Director
Linda S. Grais - Director
Scott W. Morrison - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 221015100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 68.17
Most Recent Split Date: (:1)
Beta: 0.58
Market Capitalization: $271.31 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.63 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 5.50
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -8.33%
vs. Previous Quarter: 27.78%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -24.04
12/31/24 - -90.91
ROA
06/30/25 - -
03/31/25 - -13.90
12/31/24 - -50.69
Current Ratio
06/30/25 - -
03/31/25 - 4.90
12/31/24 - 1.54
Quick Ratio
06/30/25 - -
03/31/25 - 4.90
12/31/24 - 1.54
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.72
12/31/24 - 0.51
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©